Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Impact of Ambulatory Continuous Monitoring Using Remote Monitoring Medicine Within Patient's Care Pathway Following Colorectal Surgery (CONTACT-GRECCAR 21)

NCT06850688 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2025-06-17
Last updated
2026-03-19

Condition(s) studied

Colorectal SurgeryReadmission

Investigational drug(s) / intervention(s)

Remote monitoring platform

Remote monitoring platform: EPOCA Intelligence Information System is a remote monitoring plateform. The medical device is used as a SaaS platform with restricted access for healthcare professionals. Patients and their families interact with the medical device via notifications and secure links, upon request. The medical device integrates the use of other medical devices such as oximeters, blood pressure monitors, glucometers, bracelets, etc., which are connected and whose use is also governed by their user manuals and training. Patient is monitoring via the remote monitoring platform for 30 days after hospital discharge

Study summary

The goal of this Clinical Investigation is to evaluate the effectiveness of implementing the discharge protocol of the remote monitoring platform after colorectal surgery in patients at risk of hospital readmission.

Participants will be randomized into either the "30 days of remote monitoring" group or the "conventional discharge" group. The patient returns to the site for their postoperative visit at 30 days and is contacted by phone 90 days after their surgery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria : * Man or woman over 18 years old at the time of the J0 visit, * Patient who underwent surgery less than 28 days ago, or who is scheduled to undergo colorectal surgery not managed as an outpatient procedure at the investigational center, including resection of at least one colonic or rectal segment and/or an anastomosis involving the colon or rectum, * At least one of the following two criteria: * Anticipated early discharge (within 24 hours following laparoscopic surgery without stoma and without diversion, and within 5 days following laparotomy and/or surgery with stoma and/or rectal surgery) for a procedure that is not usually managed as an outpatient surgery in routine practice, * Estimated risk of hospital readmission greater than 10% according to the nomogram of Tevis et al. \[15\], adapted to the postoperative context in digestive surgery (\>120 points according to this score). * Patient affiliated with a health insurance plan, * Patient who has signed the study consent form. Exclusion Criteria: * Discharge to a rehabilitation center requested by the patient, * Condition managed on an outpatient basis in routine practice for this type of patient, * Patient eligible for home hospitalization services, * Suicidal or hetero-aggressive risk in a patient living alone at home * Homeless patient, * Pregnant or breastfeeding women, * Patient under legal guardianship, curatorship, or protected legal status, * Patient already enrolled in an interventional postoperative follow-up study.

Primary outcome measure(s)

  • Hospitalization days — 90 days
    Cumulative duration of hospitalization days up to 90 days after the index surgery

Trial sites (14)

FacilityCityRegionStatus
CHU Angers Angers France Recruiting
Clinique Tivoli- Ducos Bordeaux France Recruiting
CHU Grenoble Grenoble France Recruiting
Centre Hospitalier Lyon-Sud Lyon France Recruiting
CHU Timone - Assistance publique-Hôpitaux de Marseille Marseille France Recruiting
Hôpital Nord - Assistance publique- Hôpitaux de Marseille Marseille France Recruiting
Institut Paoli Calmettes Marseille France Not Yet Recruiting
CHU Nantes Nantes France Recruiting
Hôpital de Bicêtre - Assistance Publique Hôpitaux de Paris Paris France Recruiting
Hôpital Saint Antoine - Assistance publique - Hôpitaux de Paris Paris France Recruiting
CHU Rennes Rennes France Recruiting
Clinique Mutualiste de l'estuaire Saint-Nazaire France Recruiting
CHU Toulouse Toulouse France Recruiting
CHRU Tours Tours France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06850688 on ClinicalTrials.gov ↗ ← All trials in France